Canadian drugmaker OncoGenex Pharmaceuticals has executed a termination agreement with Israel-based Teva Pharmaceutical Industries under which OncoGenex will regain rights to custirsen. 27 April 2015
Japanese pharma major Eisai says that its pharmaceutical sales subsidiary in Mexico, which was established in 2011, has launched the anticancer agents Halaven (eribulin mesylate) and Gliadel (carmustine implant) in Mexico. 27 April 2015
Of the five marketing approval requests reviewed at the April 2015 meeting of the European Medicines agency’s Committee for Medicinal Products for Human Use (CHMP), four received a positive opinion, and one did not. 25 April 2015
The Danish subsidiary of biotech firm DanDrit Biotech USA, seeking to develop an approved vaccine for the treatment of colorectal cancer, has signed a partnership agreement with Saudi Arabia-based Riyadh Pharma. 24 April 2015
There was a flurry of news from Anglo-Swedish pharma major AstraZeneca and its US biologics R&D unit MedImmune this morning, with the announcement of two multi-million dollar research collaborations 24 April 2015
Japanese drugmaker Ono Pharmaceuticals has submitted an additional indication application for the human anti-human programmed cell death-1 (PD-1) monoclonal antibody Opdivo (nivolumab). 23 April 2015
Pfizer says that its Xalkori (crizotinib) has received Breakthrough Therapy designation from the US Food and Drug Administration for the potential treatment of patients with ROS1-positive non-small cell lung cancer (NSCLC). 22 April 2015
US pharma giant Pfizer says that the Phase III study investigating the treatment of inotuzumab ozogamicin met its first primary endpoint. 21 April 2015
The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined in a dossier assessment whether Xtandi (enzalutamide), from Medivation and Japanese drug major Astellas Pharma, offers an added benefit over the appropriate comparator therapy for men who have metastatic prostate cancer. 21 April 2015
India’s Curadev Pharma Private says it has entered into a research collaboration and exclusive license agreement with Swiss pharma giant Roche for the development and commercialization of IDO1 and TDO inhibitors. 21 April 2015
Sweden’s Oasmia Pharmaceutical said today that its lead cancer product Paclical has received market authorization by the Russian Ministry of Health. 20 April 2015
US biotech firm Pharmacyclics, the subject of a $21 billion takeover bid from AbbVie, has released positive new data on its lead drug Imbruvica (ibrutinib). 20 April 2015
US pharma giant Merck & Co says it has submitted a supplemental Biologics License Application to the US Food and Drug Administration for Keytruda (pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of advanced non-small cell lung cancer. 20 April 2015
German drug discovery firm 4SC AG has entered into a licensing and development partnership with the Singapore-based subsidiary of Italy largest drugmaker, Menarini, for 4SC's cancer compound resminostat for the Asia-Pacific region excluding Japan. 20 April 2015
Privately-held French biotech firm Karcinolys has established Pancrealys (www.pancrealys.com), a new division within the company that has been designed to accelerate the development of its Myb34.5 oncolytic virus in pancreatic cancer. 20 April 2015
US pharma major Bristol-Myers Squibb has announced that a Phase III study evaluating Opdivo (nivolumab) versus docetaxel in previously treated patients with advanced non-squamous non-small cell lung cancer (NSCLC) was stopped early because it met its endpoint. 20 April 2015
Medical industry body Medicines Australia and other industry representatives have appeared before the Australian Senate inquiry into new, innovative and specialist oncology drugs in the country. 20 April 2015
Japan’s Center for iPS Cell Research Application (CiRA) of Kyoto University looks set to earn as much as 20 billion yen (around $168 million) from the country’s largest drugmaker, Takeda Pharmaceutical. 19 April 2015
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Applications for AVT03, a proposed biosimilar candidate to the Prolia and Xgeva (denosumab), submitted by Germany’s STADA Arzneimittel. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Bayer has entered into a collaboration with MOMA Therapeutics to develop a small molecule oncology program using the latter’s proprietary KNOMATIC platform. 9 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
ABL Bio Corp on Friday revealed that it has entered into a clinical trial collaboration and supply agreement with MSD (the ex-US/Canada trading name of Merck & Co. 7 October 2024